UNSPSC 51263007: Dapiprazole hydrochloride

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H27N5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DS9UJN1I0X, chemically known as 5,6,7,8-tetrahydro-3-(2-(4-o-tolyl-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridine monohydrochloride but more generally known as dapiprazole hydrochloride, which bears US NIH Compound Identifier 91269. European Medicines Agency schedules Dapiprazole hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01554MIG.

UNSPSC 51263007 Dapiprazole hydrochloride is a Commodity code for a pharmaceutical product. State and local governments procure under this code for clinical and community health applications, though recent solicitation activity shows substantial mismatch — the single recent opportunity tagged to this code concerns naloxone and drug deactivation systems, products unrelated to dapiprazole's ophthalmic-agent classification. The code shows little relevant recent activity grounded in its nominal pharmaceutical scope.

Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (though the opportunity contains internal date inconsistencies, with a due date of July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive sealed bidding. Deliveries were to be made quarterly to the Seminole County Community Health Building in Sanford, Florida, with vendors responsible for shipping costs. The procurement was potentially FEMA-funded and required E-Verify compliance, drug-free workplace certification, and specified insurance coverages. No other recent state or local solicitations under this code appear in the source, limiting visibility into active buying patterns or geographic concentration beyond this single Florida opportunity.